Arbutus Biopharma Corp.

Arbutus Biopharma is a therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection. Co.'s HBV pipeline consists of multiple drug candidates, with differing and complementary mechanisms of action. The candidates include: RNAi 1.0 (ARB-1467), which is Co.'s main RNA Interference (RNAi) HBV candidate designed to eliminate HBV surface antigen expression in patients chronically infected with HBV; RNAi 2.0 (ARB-1740), Co.'s follow-on RNAi HBV candidate; and Core Protein/ Capsid Assembly Inhibitors (AB-423), which is being developed as oral therapeutics for the treatment of chronic HBV infection.
  • TickerABUS
  • ISINCA03879J1003
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryCanada

Analysts

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q1 Financials; AB-729 Clinical Entry Delayed

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

ValuEngine Rating and Forecast Report for ABUS

MarketLine Department

biOasis Technologies Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's biOasis Technologies Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by biOasis Technologies Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive...

MarketLine Department

Dicerna Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Dicerna Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Dicerna Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its com...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch